{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-060124","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-09-02T20:29:56+00:00","discovered_at":"2026-09-02T20:31:10.348631+00:00","generated_at":"2026-09-02T20:31:44.397917+00:00","sec_items":["1.01","3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Senti Bio receives Nasdaq delisting notices; amends financing, $2M NSG note sale","bullets":["Nasdaq: bid price below $1.00 for 30 days; 180-day cure period to Feb 23, 2027.","Stockholders' equity deficit of $3.4M vs $2.5M requirement; plan due Oct 11, 2026.","Amendment authorizes $2.0M third-tranche note sale to NSG BioInnovation Fund.","NSG purchase satisfies Celadon's remaining note purchase obligation under Merger Agreement.","Contingent value right up to $60M tied to SENTI-202 milestones in proposed merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-060124","json":"https://secwatch.observer/filing/0001628280-26-060124.json","markdown":"https://secwatch.observer/filing/0001628280-26-060124.md","text":"https://secwatch.observer/filing/0001628280-26-060124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/0001628280-26-060124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026060124/snti-20260827.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-02T20:31:44.397917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}